A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
18 Years and older, Male and Female
VS-6766-202 (primary)
NCI-2021-01997
Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy or
VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung
cancer.
Objectives
This is a multicenter, open-label Phase 2 study designed to evaluate safety and
tolerability and efficacy of avutometinib (VS-6766) versus avutometinib (VS-6766) in
combination with defactinib in subjects with KRAS and BRAF mutant NSCLC following
treatment with an appropriate platinum-based regimen and an approved immune checkpoint
inhibitor (CPI).
Eligibility
- Male or female subjects = 18 years of age
- Histologic or cytologic evidence of NSCLC
- Known KRAS or BRAF mutation
- The subject must have received appropriate prior therapy
- Measurable disease according to RECIST 1.1
- An Eastern Cooperative Group (ECOG) performance status = 1
- Adequate organ function
- Adequate recovery from toxicities related to prior treatments
- Agreement to use highly effective method of contraceptive
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.